Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Serum Institue of India

- PMLiVE

Novavax to provide 1.1 billion COVID-19 vaccine doses to COVAX

Memorandum of understanding announced between Novavax, Gavi and the Vaccine Alliance

A Deep-Dive into the COVID-19 Pandemic and its Secondary Effects

Dr. Farah Fourcand, Author of Pandemic Manifesto, shares her experience working on the frontlines of the COVID-19 pandemic. She also dives into the psychological impact of COVID-19, lessons learned from the...

Impetus Digital

EU flag

Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU

The EU now currently has access to 2.6 billion COVID-19 vaccine doses from a range of companies

- PMLiVE

South African variant reduces antibody levels produced by Pifzer/BioNTech’s COVID-19 vaccine

Researchers noted it is 'unclear' what effect this reduction has on the vaccine's protection against the variant

- PMLiVE

UK to launch world-first COVID-19 human challenge study in the ‘next few weeks’

Initial stage of the study will involve up to 90 healthy adult volunteers who will be exposed to COVID-19

- PMLiVE

J&J applies for EU authorisation for one-dose COVID-19 vaccine

Submission is based on top-line efficacy and safety data from the phase 3 ENSEMBLE trial

- PMLiVE

EU to begin new study programme investigating COVID-19 variants

Programme is expected to launch on Wednesday

- PMLiVE

WHO grants emergency use listing for AZ/Oxford University’s COVID-19 vaccine

The emergency use listing authorises the use of the vaccine in all adults, including over-65s

- PMLiVE

US secures a further 100 million doses of Pfizer/BioNTech’s COVID-19 vaccine

US government will pay $1.95bn for additional 100 million doses

- PMLiVE

UK hits ‘significant milestone’ as 15 million people receive their first COVID-19 vaccine dose

The NHS also announced that five additional large-scale vaccination centres will open this week

- PMLiVE

AZ/Oxford University’s COVID-19 vaccine to be evaluated in children and young adults

First study to assess the safety and immune response of the vaccine in children

- PMLiVE

Roche’s anti-inflammatory drug reduces deaths in hospitalised COVID-19 patients

Tocilizumab, marketed as Actemra/RoActemra, also reduced time spent in hospital in RECOVERY trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links